Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fennec Pharmaceuticals (FENC) Cash & Equivalents: 2011-2025

Historic Cash & Equivalents for Fennec Pharmaceuticals (FENC) over the last 15 years, with Sep 2025 value amounting to $21.9 million.

  • Fennec Pharmaceuticals' Cash & Equivalents fell 45.57% to $21.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $21.9 million, marking a year-over-year decrease of 45.57%. This contributed to the annual value of $26.6 million for FY2024, which is 100.72% up from last year.
  • Per Fennec Pharmaceuticals' latest filing, its Cash & Equivalents stood at $21.9 million for Q3 2025, which was up 17.33% from $18.7 million recorded in Q2 2025.
  • Fennec Pharmaceuticals' Cash & Equivalents' 5-year high stood at $51.2 million during Q1 2024, with a 5-year trough of $12.4 million in Q3 2023.
  • For the 3-year period, Fennec Pharmaceuticals' Cash & Equivalents averaged around $25.3 million, with its median value being $21.9 million (2025).
  • Its Cash & Equivalents has fluctuated over the past 5 years, first plummeted by 58.33% in 2023, then skyrocketed by 285.74% in 2024.
  • Over the past 5 years, Fennec Pharmaceuticals' Cash & Equivalents (Quarterly) stood at $24.3 million in 2021, then grew by 22.26% to $23.8 million in 2022, then plummeted by 44.19% to $13.3 million in 2023, then skyrocketed by 100.72% to $26.6 million in 2024, then crashed by 45.57% to $21.9 million in 2025.
  • Its Cash & Equivalents was $21.9 million in Q3 2025, compared to $18.7 million in Q2 2025 and $22.7 million in Q1 2025.